BR112022001395A2 - Métodos para administrar anticorpos anti-siglec-8 e corticosteroides - Google Patents
Métodos para administrar anticorpos anti-siglec-8 e corticosteroidesInfo
- Publication number
- BR112022001395A2 BR112022001395A2 BR112022001395A BR112022001395A BR112022001395A2 BR 112022001395 A2 BR112022001395 A2 BR 112022001395A2 BR 112022001395 A BR112022001395 A BR 112022001395A BR 112022001395 A BR112022001395 A BR 112022001395A BR 112022001395 A2 BR112022001395 A2 BR 112022001395A2
- Authority
- BR
- Brazil
- Prior art keywords
- siglec
- methods
- corticosteroids
- antibodies
- administering anti
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882330P | 2019-08-02 | 2019-08-02 | |
| PCT/US2020/044583 WO2021026021A1 (en) | 2019-08-02 | 2020-07-31 | Methods of administering anti-siglec-8 antibodies and corticosteroids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022001395A2 true BR112022001395A2 (pt) | 2022-06-07 |
Family
ID=74504001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022001395A BR112022001395A2 (pt) | 2019-08-02 | 2020-07-31 | Métodos para administrar anticorpos anti-siglec-8 e corticosteroides |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220257758A1 (https=) |
| EP (1) | EP4007606A4 (https=) |
| JP (1) | JP2022542472A (https=) |
| KR (1) | KR20220044203A (https=) |
| CN (1) | CN114466664A (https=) |
| AU (1) | AU2020325097A1 (https=) |
| BR (1) | BR112022001395A2 (https=) |
| CA (1) | CA3149484A1 (https=) |
| IL (1) | IL290111A (https=) |
| MX (1) | MX2022001403A (https=) |
| WO (1) | WO2021026021A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL270304B2 (en) * | 2017-05-05 | 2024-07-01 | Allakos Inc | Methods and preparations for the treatment of inflammatory disorders in the digestive system |
| WO2021081411A1 (en) * | 2019-10-24 | 2021-04-29 | Allakos Inc. | Methods and compositions for treating irritable bowel syndrome and functional dyspepsia |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| WO2024043940A1 (en) * | 2022-08-25 | 2024-02-29 | Allakos Inc. | Methods and compositions for treating atopic dermatitis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ720769A (en) * | 2013-12-09 | 2022-10-28 | Allakos Inc | Anti-siglec-8 antibodies and methods of use thereof |
| JP2020504135A (ja) * | 2017-01-06 | 2020-02-06 | アラコス インコーポレイテッド | 慢性閉塞性肺障害を処置するための方法および組成物 |
| EP3618868A4 (en) * | 2017-05-05 | 2021-02-24 | Allakos Inc. | METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES |
| IL270304B2 (en) * | 2017-05-05 | 2024-07-01 | Allakos Inc | Methods and preparations for the treatment of inflammatory disorders in the digestive system |
-
2020
- 2020-07-31 KR KR1020227006136A patent/KR20220044203A/ko not_active Ceased
- 2020-07-31 US US17/630,474 patent/US20220257758A1/en active Pending
- 2020-07-31 CA CA3149484A patent/CA3149484A1/en active Pending
- 2020-07-31 WO PCT/US2020/044583 patent/WO2021026021A1/en not_active Ceased
- 2020-07-31 CN CN202080067793.2A patent/CN114466664A/zh active Pending
- 2020-07-31 BR BR112022001395A patent/BR112022001395A2/pt not_active IP Right Cessation
- 2020-07-31 MX MX2022001403A patent/MX2022001403A/es unknown
- 2020-07-31 JP JP2022506612A patent/JP2022542472A/ja active Pending
- 2020-07-31 AU AU2020325097A patent/AU2020325097A1/en not_active Abandoned
- 2020-07-31 EP EP20849085.4A patent/EP4007606A4/en not_active Withdrawn
-
2022
- 2022-01-25 IL IL290111A patent/IL290111A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3149484A1 (en) | 2021-02-11 |
| EP4007606A4 (en) | 2023-09-27 |
| KR20220044203A (ko) | 2022-04-06 |
| AU2020325097A1 (en) | 2022-03-03 |
| CN114466664A (zh) | 2022-05-10 |
| JP2022542472A (ja) | 2022-10-03 |
| IL290111A (en) | 2022-03-01 |
| WO2021026021A1 (en) | 2021-02-11 |
| EP4007606A1 (en) | 2022-06-08 |
| MX2022001403A (es) | 2022-03-25 |
| US20220257758A1 (en) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022001395A2 (pt) | Métodos para administrar anticorpos anti-siglec-8 e corticosteroides | |
| BR112017026189A2 (pt) | tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4 | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
| BR112016030686A2 (pt) | anticorpos anti tau humanizados | |
| BR112022000719A2 (pt) | Anticorpo anti-tau ou um fragmento de ligação ao antígeno do mesmo, polinucleotídeo, vetor de expressão, célula hospedeira, método para produção do anticorpo anti-tau ou fragmento de ligação ao antígeno do mesmo, hibridoma, composição farmacêutica, composição para diagnosticar uma doença neurológica degenerativa, kit, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo e método para prevenir ou tratar uma doença neurológica degenerativa | |
| BR112016008010A2 (pt) | uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose | |
| BR112017005517A2 (pt) | anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes | |
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| BR112021019107A2 (pt) | Anticorpos contra amiloide-beta piroglutamato e usos dos mesmos | |
| BR112021019262A2 (pt) | Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose | |
| BR112021012056A2 (pt) | Inibidor da expressão gênica do hbv, agente que reduz a carga antigênica de hbv, composições para uso no tratamento de uma infecção crônica por hbv, usos de um inibidor da expressão gênica do hbv e de um agente que reduz a carga antigênica de hbv, métodos de tratamento da infecção crônica por hbv e kit | |
| BR112023001143A2 (pt) | Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo | |
| BR112022026999A2 (pt) | Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas | |
| BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
| BR112022015151A2 (pt) | Método para reduzir ou prevenir progressão de um tumor ou tratar câncer, e, composição | |
| BR112022011570A2 (pt) | Anticorpos anti-mertk e métodos de uso dos mesmos | |
| BR112021024109A2 (pt) | Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática | |
| BR112023002085A2 (pt) | Métodos para tratar hipercolesterolemia refratária envolvendo inibidor de angptl3 | |
| BR112021016596A2 (pt) | Anticorpo anti-pd-l1 e uso do mesmo | |
| MX2024005430A (es) | Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau. | |
| BR112023015422A2 (pt) | Anticorpo anti-c1s | |
| BR112018071972A2 (pt) | métodos para tratamento ou prevenção de uma doença ou distúrbio de fígado, para tratamento de câncer de fígado e para tratamento de inflamação no fígado, trato biliar ou pâncreas de um animal, alfa-defensina e/ou ss-defensina de mamífero e/ou uma catelicidina e/ou um análogo de glp-1, e, uso dos mesmos. | |
| BR112022008095A2 (pt) | Métodos e composições para o tratamento da síndrome de rett | |
| BRPI0416591A (pt) | métodos e reagentes para o tratamento de distúrbios inflamatórios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: ALLAKOS INC. (US) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2841 DE 17-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |